Content Status
Type
Linked Node
Drugs Not Included in Groups A - C and Rationale for Non-inclusion
Learning ObjectivesDrugs Not Included in Groups A - C and Rationale for Non-inclusion
There are some anti-TB drugs that are not included in the conventional Groups A, B and C of anti-TB medicines.
The table below shows these drugs and the rationale for not including them in longer Multidrug-resistant TB (MDR-TB) regimens.
| DRUGS NOT INCLUDED IN GROUPS A - C | RATIONALE FOR NON-INCLUSION OF THESE DRUGS IN GROUPS A-C |
|---|---|
| Kanamycin and Capreomycin |
They are associated with poorer outcomes when used in treatment and are, therefore, no longer recommended for use in MDR-TB regimens. |
| Gatifloxacin |
Quality-assured preparations of Gatifloxacin are currently not available in the market following its withdrawal from the market due to concerns about dysglycaemias. |
| Thioacetazone |
Thioacetazone was not used at all for the treatment of MDR-TB cases. It will unlikely have a role in longer MDR-TB regimens, and it is currently not available in a quality-assured formulation. |
| Clavulanic acid |
Should be included in MDR-TB regimens only as a companion agent to the carbapenems (Imipenem-Cilastatin (Imp-Cln) and Meropenem (Mpm)). When used in this way, it should be given with every dose of carbapenem and should not be counted as an additional effective TB agent. |
Resources
- Guidelines for Programmatic Management of Drug-resistant Tuberculosis in India, March 2021.
- WHO Consolidated Guidelines on Tuberculosis: Module 4 – Treatment: Drug-resistant Tuberculosis Treatment, 2020.
- Companion Handbook to the WHO Guidelines for the Programmatic Management of Drug-resistant Tuberculosis, 2014.
Kindly provide your valuable feedback on the page to the link provided HERE
Content Creator
Reviewer
- Log in to post comments